The Readout Loud

STAT
undefined
Dec 14, 2023 • 35min

286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

FTC blocks Sanofi-Maze Therapeutics deal, Pfizer's downbeat future, Vertex's next big thing, and Reed Jobs' journey into biotech venture capital.
undefined
Dec 7, 2023 • 37min

285: CRISPR history, biotech struggles, & a big week for deals

Megan Molteni discusses the history and future of CRISPR-based medicine and the expected FDA approval of the first CRISPR-based medicine. Bruce Booth joins to discuss the challenges faced by the biotech industry and prospects for optimism in 2024.
undefined
Nov 30, 2023 • 29min

284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

AbbVie, a company spending $10 billion on a cancer-focused company on its first FDA approval. Implications for biotech in 2023 and oncology. Safety concerns for CAR-T cancer treatment. Slumping industry job market. Curious explanations for clinical failures.
undefined
11 snips
Nov 16, 2023 • 31min

283: A CRISPR milestone, algorithms amok, & biotech mixology

Investigative reporter Casey Ross reveals how UnitedHealth Group used an algorithm to deny patient care for profit. Biotech veteran Michael Gilman talks about being a startup CEO in the economic downturn and shares cocktail recipes. They also discuss the approval of a groundbreaking CRISPR-based medicine.
undefined
Nov 13, 2023 • 30min

From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

This podcast discusses the ongoing problem of surprise ambulance bills in the US. It highlights the financial burden on patients and the difficulty in finding a fair solution. Personal stories are shared to emphasize the high costs and frustration faced by patients. Different approaches taken by states and the need for a public reckoning in emergency services are explored. The potential consequences of congressional inaction are also discussed, but there is a glimmer of hope with one person receiving a zero-dollar bill due to an insurance error.
undefined
Nov 9, 2023 • 37min

282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

This podcast explores the scientific backstory of radiopharmaceuticals, Eli Lilly's new obesity drug, a biotech implosion, and shareholder activism. They also discuss the approval and pricing of Lilly's weight loss drug, upcoming cardiovascular outcome study for Novo Nordisk's WeGoV, and updates in the pharmaceutical industry. Additionally, they delve into the history of the radiopharmaceutical Zevelin and a bittersweet day for IDEC and Zevelin employees during an FDA advisory panel meeting.
undefined
11 snips
Nov 2, 2023 • 32min

281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

Biotech consultant Frank David explains subgroup analyses and how they can be misleading. The podcast also discusses the future of Sarepta and the retirement of a biotech stalwart.
undefined
Oct 26, 2023 • 30min

280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

The podcast discusses the highlights of a recent oncology conference, including advancements in cancer-treating technology. It also covers the future of Alzheimer's disease treatment, a multibillion-dollar biotech deal, and the rise of biotech venture capital. The hosts explore the incredible math behind a biotech investment that turned $50 million into $5 billion. They also discuss the challenges faced by the biotech industry, recent developments in Alzheimer's treatment, and advancements in antibody-drug conjugates for cancer treatment.
undefined
Oct 19, 2023 • 33min

279: Live from the 2023 STAT Summit

Live from the 2023 STAT Summit, the hosts discuss genome editing milestones, twists in ALS treatments, and the polarizing process of pronouncing words in biotech. They also explore the potential impact of in vivo gene editing therapy, debates over pronunciation of acronyms and drug names, and the future of neurodegenerative diseases research.
undefined
Oct 12, 2023 • 33min

278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

The podcast discusses Bristol Myers Squibb's acquisition of Mirati Therapeutics, the rejection of a treatment by Al Nylon, the impact of GLP-1 drugs on the Nash treatment market, and advancements in genetic engineering using CRISPR technology in animals.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app